Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

PCORI Board Will Add New Consumer/Patient Rep After One Member Joins Senate HELP Committee Staff

This article was originally published in The Pink Sheet Daily

Executive Summary

GAO will select replacement from previous nominations.

You may also be interested in...



Personalized Medicine Coalition Submits List Of Drug Firm Nominees For PCORI Methodology Committee

PhRMA and BIO decline to make nominations. GAO announces replacement for PCORI board.

Personalized Medicine Coalition Submits List Of Drug Firm Nominees For PCORI Methodology Committee

PhRMA and BIO decline to make nominations. GAO announces replacement for PCORI board.

PCORI Forming CER Methodology Committee

Nominations for the upcoming Patient-Centered Outcomes Research Institute’s influential methodology committee may include names previously submitted, but not selected, for the institute’s board of governors, the General Accountability Office says in a notice published in the Sept. 28 Federal Register.

Related Content

Topics

UsernamePublicRestriction

Register

PS071379

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel